Access to Medicine
SCP 25
December 12 to December 15, 2016 WIPO’s Page on the Meeting SCP 25: Opening statement of Knowledge Ecology International SCP25: Statement of Asia Pacific Group on Patents and Health SCP25: South Africa’s Experience Related to the Topic of Access to… Continue Reading
SCP 27
December 11 to December 15, 2017 WIPO’s Page for the Meeting SCP27: WIPO patent committee agrees to future work on patent oppositions, exceptions and limitations, and patents and health SCP27: South Africa urges WIPO to invite UNHLP Co-Chairs to present… Continue Reading
Trade Policy Reviews
KEI page on the World Trade Organization’s (WTO) Trade Policy Reviews All members of the WTO are subject to review under the Trade Policy Review Mechanism (TPRM). The TPRM takes place in the “Trade Policy Review Body which is actually… Continue Reading
18 members of the House of Representatives call for compulsory license on patents for HCV treatments
Representative Ro Khanna (D-CA-17) was joined by 17 other members of Congress in calling upon Department of Health and Human Services Secretary Alex Azar to issue a compulsory license on patents for medications to treat hepatitis C, by exercising 28… Continue Reading
October 2017: Dueling narratives on compulsory licensing emerge from the WTO TRIPS Council
The October 2017 meeting of the WTO TRIPS Council witnessed heated discussions on compulsory licensing within the context of IP and the Public Interest. As reported earlier by Knowledge Ecology International, on 31 May 2017, Brazil, China, Fiji, India, and… Continue Reading
Timeline on Global Health Norm setting on non-communicable diseases
2000 May 20, 2000 – WHO passes WHA 53.17, which calls for research, prevention, collaboration, and capacity building to prevent and control noncommunicable diseases 2002 April 13, 2002 –The Salt Institute and other industry lobbying groups release their first comments… Continue Reading
NIH Declines Request for the Budget for Clinical Trials Involving CAR T technology to be licensed to Kite/Gilead
On February 14, the NIH was asked what the budget was for the Phase 1 clinical trial of the anti-CD30 CAR T technology that is the subject of a proposed exclusive patent license to Kite/Gilead. The clinicaltrials.gov identifier for the… Continue Reading